健康元药业集团股份有限公司2025年半年度报告（英文版）

Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2025 1 / 228 Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2025 2 / 228 Important Notice Ⅰ The Board of Directors (the “Board”), the Board of Supervisors and directors, supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of the interim report (the “Report”), and that there are no false representations, misleading statements or material omissions contained in the Report, and severally and jointly accept responsibility. Ⅱ All the directors of the Company attended the Board meeting. Ⅲ The interim report of the Company is unaudited. Ⅳ Mr. Zhu Baoguo (朱保国), the person-in-charge of the Company, Mr. Qiu Qingfeng (邱庆丰), the person-in-charge of the Company's accounting work, and Ms. Guo Chenlu (郭琛璐), the person-in-charge of the accounting department (the head of the accounting department), declare that they hereby warrant the truthfulness, accuracy and completeness of the financial statements contained in the Report. Ⅴ Profit distribution plan or plan for conversion of capital reserve to share capital approved by the Board during the Reporting Period Not applicable VI Risk declaration for the forward-looking statements √Applicable □N/A The Report contains forward-looking statements which involve the future plans, development strategies, etc. of the Company, yet do not constitute substantive undertakings of the Company to investors. Investors should exercise caution prior to making investment decisions. VII Whether there is non-operating use of funds by the controlling shareholder and their related parties No VIII Whether there is a violation of the prescribed decision-making procedures to provide external guarantees No IX Whether more than half of directors cannot warrant the truthfulness, accuracy and completeness of the Report disclosed by the Company No Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2025 3 / 228 X Significant risk warnings There is no exceptionally significant risk that will have a material impact on the production and operation of the Company during the Reporting Period. In this Report, the Company has elaborated on the risks and countermeasures that the Company may face in the course of production and operation, including industry policy risk, market risk, risk of safety and environmental protection, risk in price and supply of raw materials and R&D risk. For more information, please refer to “Potential risks” section in Chapter 3 Management Discussion and Analysis. XI Others □Applicable √N/A Joincare Pharmaceutical Group Industry Co., Ltd. Interim Report 2025 4 / 228 Table of Contents Important Notice .............................................................................................................................